Published in Health and Medicine Week, August 15th, 2005
"New thrombin-activatable fibrinolysis inhibitor (TAFI) assays are necessary for studying the role of this fibrinolysis inhibitor in cardiovascular disease. The identification of a functional single nucleotide polymorphism (SNP) (1040C/T) leading to a TAFI-variant with increased stability but lower antigen levels has made the determination of functional activity even more essential," investigators in the Netherlands report.
A.H. Guimaraes and colleagues of TNO Prevention and Health in Leiden wrote, "Therefore, we developed a new assay for the functional...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.